知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

63 records (took 0.117 seconds)

    CYTOPLASMIC TRANSFER TO DE-DIFFERENTIATE RECIPIENT CELLS
    2.
    发明申请
    CYTOPLASMIC TRANSFER TO DE-DIFFERENTIATE RECIPIENT CELLS 审中-公开
    细胞色素转移以分化受体细胞

    公开(公告)号：US20150132853A1

    公开(公告)日：2015-05-14

    申请号：US14302384

    申请日：2014-06-11

    Applicant: Advanced Cell Technology, Inc.

    Inventor： Karen B. Chapman

    IPC: C12N5/0735 ,  C12N5/071

    CPC classification number: C12N5/0606 ,  A61K35/12 ,  A61K48/00 ,  C12N5/0602 ,  C12N5/0696 ,  C12N5/16 ,  C12N9/1241 ,  C12N15/79 ,  C12N15/873 ,  C12N2501/00 ,  C12N2503/00 ,  C12N2506/00 ,  C12N2510/04 ,  C12N2517/10

    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.

    Abstract translation: 提供了通过从更原始，较不分化的细胞类型例如卵母细胞或卵裂球引入细胞质来去分化或改变所需“受体”细胞例如人体细胞的寿命的方法。 这些方法可以用于产生胚胎干细胞，并且通过允许所需细胞经受多种遗传修饰而不变老，提高基因治疗的效率。 这样的细胞质可以被分馏和/或进行消减杂交，并通过重组方法鉴定和产生活性物质（足以去分化）。

    METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS
    3.
    发明申请
    METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS 审中-公开
    RPE细胞的生产方法和RPE细胞的组成

    公开(公告)号：US20150086512A1

    公开(公告)日：2015-03-26

    申请号：US14254833

    申请日：2014-04-16

    Applicant: Advanced Cell Technology, Inc.

    Inventor： Christopher Malcuit ,  Linda Lemieux ,  William Holmes ,  Pedro Huertas ,  Lucy Vilner

    IPC: C12N5/079 ,  A61K35/30

    CPC classification number: C12N5/0621 ,  A61K35/12 ,  A61K35/30 ,  C12N2501/10 ,  C12N2501/734 ,  C12N2506/02 ,  C12N2509/00 ,  C12N2533/54

    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.

    Abstract translation: 本发明提供了用于从人胚胎干细胞或其他人多能干细胞产生RPE细胞的改进方法。 本发明还涉及源自人胚胎干细胞或其他人多能或多能干细胞的人视网膜色素上皮细胞。 衍生自胚胎干细胞的hRPE细胞与成体和胎儿衍生的RPE细胞分子不同，并且也不同于胚胎干细胞。 本文所述的hRPE细胞可用于治疗视网膜退行性疾病。

    DERIVATION OF EMBRYONIC STEM CELLS
    4.
    发明申请
    DERIVATION OF EMBRYONIC STEM CELLS 有权
    胚胎干细胞的衍生

    公开(公告)号：US20140377865A1

    公开(公告)日：2014-12-25

    申请号：US14154163

    申请日：2014-01-13

    Applicant: ADVANCED CELL TECHNOLOGY, INC.

    Inventor： ROBERT P. LANZA ,  YOUNG GIE CHUNG

    IPC: C12N5/0735

    CPC classification number: C12N5/0606 ,  A61K35/545 ,  C12N5/0604 ,  C12N15/873 ,  C12N2501/119 ,  C12N2501/603 ,  C12N2501/91 ,  C12N2502/02 ,  C12N2506/02

    Abstract: This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.

    Abstract translation: 本发明提供用于衍生胚胎干细胞，那些细胞和细胞系的新颖方法，以及用于治疗和研究目的而不破坏胚胎的细胞的用途。 它还涉及在植入胚胎之前建立和储存自体干细胞系的新方法，例如与生殖治疗如IVF结合。

    LASER ISOLATION OF VIABLE CELLS
    5.
    发明申请
    LASER ISOLATION OF VIABLE CELLS 审中-公开
    激光分离可变电池

    公开(公告)号：US20120258451A1

    公开(公告)日：2012-10-11

    申请号：US13441617

    申请日：2012-04-06

    Applicant: Irina Vitaly KLIMANSKAYA

    Inventor： Irina Vitaly KLIMANSKAYA

    IPC: C12N13/00 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/53

    CPC classification number: C12N5/0621 ,  C12N2509/00 ,  G01N2001/2886

    Abstract: Methods for laser microdissection isolation of viable cells are provided. Cells of a desired type may be isolated from a diverse population, optionally with detection and exclusion of undesired cells. Desired cells may be isolated from a population that arose from differentiation of pluripotent cells, preferably embryonic stem cells or induced pluripotent stem cells, and undifferentiated stem cells may be detected and excluded from selection including the isolation of RPE cells sleeted based on morphology (e.g., characteristic mottled appearance) from a population of ES cells. The cells isolated by these methods, including RPE cells, may be essentially free of undifferentiated cells and thus suitable for use in cell-based therapies.

    Abstract translation: 提供了活细胞激光显微切割分离方法。 所需类型的细胞可以从不同群体分离​​，任选地检测和排除不需要的细胞。 所需的细胞可以从多能细胞分化产生的群体分离，优选胚胎干细胞或诱导的多能干细胞，并且可以检测未分化的干细胞，并将其排除在选择之外，包括基于形态学分离的RPE细胞（例如， 特征斑驳的外观）从ES细胞群体。 通过这些方法分离的细胞（包括RPE细胞）可以基本上不含未分化细胞，因此适用于基于细胞的疗法。

    HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS
    8.
    发明申请
    HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS 有权
    HEMANGIO COLONY成形细胞和非恒定HEMANGIO细胞

    公开(公告)号：US20110064705A1

    公开(公告)日：2011-03-17

    申请号：US12991096

    申请日：2009-05-06

    Applicant: Robert Lanza ,  Shi-Jiang Lu

    Inventor： Robert Lanza ,  Shi-Jiang Lu

    IPC: A61K35/12 ,  C12N5/071 ,  C40B50/06 ,  C12N5/078 ,  C40B40/02 ,  A61P37/06 ,  A61P9/10

    CPC classification number: C12N5/0647 ,  A61K35/12 ,  A61K35/28 ,  A61K35/44 ,  A61K38/13 ,  A61K45/06 ,  A61K2035/124 ,  A61N5/10 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/26 ,  C12N2506/02 ,  C12N2506/45

    Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow.

    Abstract translation: 公开了在体外产生和扩大人血管瘤集落形成细胞和非移植血管瘤细胞的方法以及扩增和使用这些细胞的方法。 该方法允许生产大量的血管瘤集落形成细胞，非移植血管瘤细胞以及衍生细胞，如造血细胞和内皮细胞。 通过所公开的方法获得的细胞可用于各种研究，临床和治疗应用。 人类非移植血管瘤细胞是与成血管细胞和人类血管瘤集落形成细胞相关但不同的新型祖细胞群。 本发明还提供包含血管瘤集落形成细胞，非移植血管瘤细胞或与其分化的细胞的组合物，制剂和溶液。 组合物，制剂和溶液包括冷冻保存的制剂和基本纯化的制剂，以及与可以移入骨髓的相关成血管细胞祖细胞类型组合配制的混合组合物。

Patent Agency Ranking